Our Story

Our mission is to improve human health through environmental biodynamics.

LinusBio is a patient-centric, precision exposome medicine company headquartered in New York, NY. 

Originating from the world’s leading exposome laboratory at Mount Sinai Health System, Linus has developed a technology platform that builds on breakthroughs in exposome sequencing by trailblazing researchers Drs. Manish Arora, Christine Austin and Paul Curtin.

The Company’s program pipeline comprises precision exposome medicine biomarkers and target discovery across disease domains for which historically no molecular endpoints have been available in medical practice or for clinical trials, including CNS (autism spectrum disorder, amyotrophic lateral sclerosis), gastroenterology (inflammatory bowel disease), renal disease and oncology. 


  • 2013

    The world’s first Institute for Exposomic Research established at Mount Sinai in 2013 with Manish Arora, PhD as the co-founder and director of environmental exposure and precision environmental medicine laboratories, leading a team of over 50 scientists advancing research in a vast array of diseases that are national health priorities, including autism, ALS, cancers, and gastrointestinal disorders

  • 2016

    Dr. Manish Arora awarded the U.S. Presidential Early Career Award for Scientists and Engineers (PECASE)

  • 2019

    NIH grants of $25 million awarded to Dr. Arora and researchers at the Mt. Sinai Institute for Exposomic Research

  • 2020
    • LinusBio incorporated
    • Initial patents filed
  • 2021
    • Spinoff from Mt. Sinai completed, and worldwide license and collaboration agreement announced
    • Strategic partnerships with two global biopharma companies initiated
    • FDA Breakthrough
      Device designation awarded to StrandDxTM – ASD to assess the likelihood of autism in children < 18 months old and to aid in diagnosis
      of autism
  • 2022
    • Medical Device Regulatory Pathway for StrandDx™- ASD continued with FDA feedback and meetings
    • Closed Series A financing round with Bow Capital and GPV as co-leads
  • future
    • Establish licensed proprietary laboratory to make StrandDx™-  ASD available as a laboratory developed test for pilot programs
    • Determine novel molecular endpoints for collaboration partners’ drug discovery and clinical trials